

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No.: 09/079,785

Filed: May 15, 1998

For: CD30 LIGAND



Docket No.: 2804-H

Group Art Unit: 1646

Examiner: L. Spector

681646  
#15  
Ross  
8/4/99  
CONT'D

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

JUL 23 1999

Dear Sir:

TECH CENTER 1600/2900

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicants hereby disclose information known to them which may be material to the patentability of the subject invention. Kindly acknowledge receipt of this Statement, and make the references cited on the attached Form PTO-1449 of record in the above-identified application.

Citation of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103. Applicants specifically reserve the right to antedate any such material, as by a showing under 37 C.F.R. §1.131 or other method.

Four of the references listed on the attached Form PTO-1449 were cited in a Supplementary Search Report received in the corresponding European patent application. EP 412,050 A1, Armitage et al., and Zsebo et al. were cited as "category A: technological background". WO 87/07144 was cited as being relevant to only one claim, which is a claim directed to an "antisense or sense oligonucleotide that can inhibit transcription or translation of CD30-L, comprising a sequence of at least 14 nucleotides corresponding to a DNA sequence according to claim 5 or its DNA or RNA complement". Copies of these four references are enclosed.


Each of the remaining references on the enclosed Form PTO-1449 was cited by, or submitted to, the U.S. P.T.O. in USSN 08/580,014, filed December 20, 1995, USSN 08/225,989, filed April 12, 1994, or USSN 07/966,775, filed October 27, 1992, from which the present application claims priority. According to 37 C.F.R. §1.98(d), copies of references submitted in such prior applications need not be enclosed with the present Statement.

Certain of the cited references were published after the filing date of one or more of the prior applications, from which the present application claims priority. Applicants submit that the claims of the above-captioned application are directed to subject matter which is patentably distinct from the disclosures of the cited references.

Neither a first office action on the merits nor an notice of allowance has been mailed in the subject application. Thus, no fee is believed to be due in connection with this Statement.

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101

Respectfully submitted,



Kathryn A. Anderson  
Registration No. 32,172

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date July 15, 1999 Signed: Camilla C. Edwards